IsoRay(NYSEAMERICAN：ISR)股价突破200日移动均线0.00美元

Isoray, Inc. (NYSEAMERICAN:ISR – Get Rating)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.31. Isoray shares last traded at $0.29, with a volume of 5,244 shares traded.

The stock has a market capitalization of $41.19 million, a price-to-earnings ratio of -5.80 and a beta of 0.92.

Get

Isoray

alerts:

Isoray (NYSEAMERICAN:ISR – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The healthcare company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The business had revenue of $2.91 million for the quarter, compared to the consensus estimate of $3.15 million. Isoray had a negative net margin of 48.05% and a negative return on equity of 9.19%. On average, research analysts expect that Isoray, Inc. will post -0.04 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in ISR. Perkins Capital Management Inc. boosted its holdings in shares of Isoray by 80.4% in the 4th quarter. Perkins Capital Management Inc. now owns 2,801,000 shares of the healthcare company's stock valued at $1,086,000 after acquiring an additional 1,248,000 shares during the last quarter. Taylor & Morgan Wealth Management LLC purchased a new stake in Isoray during the fourth quarter worth $132,000. Highland Private Wealth Management boosted its holdings in Isoray by 14.8% during the fourth quarter. Highland Private Wealth Management now owns 972,038 shares of the healthcare company's stock worth $377,000 after buying an additional 125,000 shares in the last quarter. Bard Associates Inc. boosted its holdings in Isoray by 8.1% during the first quarter. Bard Associates Inc. now owns 669,200 shares of the healthcare company's stock worth $243,000 after buying an additional 50,000 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Isoray during the third quarter worth $31,000. 11.16% of the stock is currently owned by institutional investors and hedge funds.

Isoray Company Profile (NYSEAMERICAN:ISR)

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

Read More

• Get a free copy of the StockNews.com research report on Isoray (ISR)
• Using MarketBeat Market Data Tools To Find Strong Stocks in a Bear Market
• Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
• MarketBeat: Week in Review 6/27 – 7/1
• Accolade Moves Higher But Growth Is Slowing
• ZIM Integrated Shipping Services (ZIM): Don't Miss This Dividend

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.